29 results
Thumbnail

D1.233 - Pembrolizumab IgE mediated drug hypersensitivity reaction and successful desensitisation

Thumbnail

D1.234 - The Importance of Differential Diagnosis in DRESS Syndrome: Review of 2 Cases

Thumbnail

D1.235 - Clorhexidine allergy in northern area of Seville

Thumbnail

D1.236 - Clinical Outcomes of Neuromuscular Blocking Agent Rechallenge Based on Skin Prick Test in Patients with Intraoperative Anaphylaxis

Thumbnail

D1.237 - What Do Drug Skin Tests Tell Us About Quinolone Allergy? Adult Allergy Reference Center Experience

Thumbnail

D1.238 - Urgent desensitization to amiodarone

Thumbnail

D1.239 - Nonsteroidal anti-inflammatory drug cross-hypersensitivity phenotypes show high carbonyl levels

Thumbnail

D1.243 - L-asparaginase desensitization in children

Thumbnail

D1.244 - Retrospective Analysis of Adverse Reactions to Iodinated Contrast Media: Experience in 165 Patients

Thumbnail

D1.245 - Platinum salt hypersensitivity: Experience of our Center

Thumbnail

D1.246 - Cephalosporin Allergy in Children

Thumbnail

D1.247 - Tolerance to intravenous sodium heparin despite a positive subcutaneous challenge test: A case report

Thumbnail

D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab

Thumbnail

D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Thumbnail

D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Thumbnail

D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic

Thumbnail

D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates

Thumbnail

D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab

Thumbnail

D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results

Thumbnail

D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years